A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.
|
| Abstract |
The C-MOPP regimen, consisting cyclophosphamide, vincristine, prednisolone and procarbazine, has been used for treatment of non-Hodgkin lymphoma; however, there are few reports of this therapy against aggressive lymphoma. We performed a retrospective analysis of previously treated 89 patients who had received C-MOPP therapy from 1999 to 2013 at our institution. Median age was 67 (range, 22-81) years. Twenty-eight patients obtained CR, 5 obtained PR, and overall response rate was 37% (33/89). The estimated 1-year overall survival and progression-free survival rates were 61 and 33%, respectively. Major grade > 2 toxicities were leucopenia (55%) and neutropenia (52%). Efficacy and toxicity were in line with other recent studies involving new agents, given that the subjects mainly consisted of elderly outpatients. These data provide a rationale for the use of C-MOPP as a current control treatment arm when the response to new cancer therapy agents is evaluated.
|
|---|---|
| Authors | Ryoko Fukushima, Yukio Kobayashi, Suguru Fukuhara, Ken'ichi Miyamoto, Wataru Munakata, Dai Maruyama, Sung-Won Kim, Takashi Watanabe, Hirokazu Taniguchi, Akiko Maeshima, Kensei Tobinai |
| Journal | Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 28 Issue 2 Pg. 116-22 (Apr 2016) ISSN: 1973-9478 [Electronic] England |
| PMID | 27093518 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!